… Topotecan is currently the only drug approved in Europe in a second-line setting for the
treatment of small-cell lung cancer. … superior to topotecan as a second-line treatment in patients …

… was active in this population given that chemotherapy plus … Lurbinectedin compares favorably
to other drugs on the list of … phase III study of lurbinectedin/doxorubicin versus topotecan …

… targeted therapy and immunotherapy have also been actively tested … After relapse, topotecan
is the only second-line drug … phase II study of weekly topotecan as second-line therapy for …

… Until June 2020, oral or intravenous topotecan was the only drug … two randomized phase
III trials, where topotecan showed extended … Lurbinectedin is also being actively evaluated in …

… ones, have shown that A is active and relatively well-tolerated in … A phase III randomized trial
comparing A with topotecan in … alkylating drug Lurbinectedin (L) was evaluated in a phase II …

… , few novel chemotherapy drugs have been developed in the latest … As a second-line treatment,
a phase III randomised trial … , second-line belotecan has been compared to topotecan in a …

… rovalpituzumab tesirine versus topotecan in the second-line setting was … topotecan followed
by weekly doxorubicin is a safe and active regimen in patients with relapsed small cell lung …

… Lurbinectedin was active as second-line therapy for SCLC in … Lurbinectedin could represent
a potential new treatment for patients … Topotecan is the only approved drug for second-line …

… the treatment of relapsed SCLC, as second-line treatment for … cancer, and stage IVB
recurrent/persistent cervical cancer. In … and Drug Administration (FDA) approved for the treatment …

… by the Food and Drug Administration as second line for SCLC … , was the only second-line
treatment approved for SCLC … of topotecan was evaluated in a randomized phase III clinical …